Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

NCT05145907 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: TJ107 +Pembrolizumab

Sponsor

TJ Biopharma Co., Ltd.